Therefore, we sought to assess D2R protein expression by immunostaining in paired chemotherapy-naïve and chemotherapy-resistant specimens from a cohort of SCLC-A patients (Supplementary Table 1). The gene discussed is DRD2; the disease is small cell lung carcinoma.